A novel cancer therapy based on oxygen radicals.
The antitumor effect of oxygen radicals produced by hypoxanthine and xanthine oxidase reaction was studied in an experimental rabbit model. VX2 carcinomas were transplanted into rabbit hind legs. Hypoxanthine was administered continuously through the ear vein, while xanthine oxidase was administered simultaneously through the femoral artery. As a result, hypoxanthine and xanthine oxidase reacted only in the hind leg, and superoxide was produced in that area. The volume of the VX2 carcinoma was measured immediately prior to treatment and 7 days later. As an index of lipid peroxidation, thiobarbituric acid-reactive substances in the tumor tissue were measured 60 min following infusion of hypoxanthine and xanthine oxidase. Tumor growth was suppressed significantly by the hypoxanthine-xanthine oxidase reaction, and thiobarbituric acid-reactive substances in the tumor tissue infused with hypoxanthine and xanthine oxidase were significantly increased. In addition, the antitumor effect of the hypoxanthine and xanthine oxidase reaction was significantly inhibited by the administration of superoxide dismutase and catalase. Pathological examination showed that oxygen radicals produced by hypoxanthine and xanthine oxidase reaction were selectively more destructive for VX2 carcinoma tissue than muscle tissue surrounding the tumor region. These results suggest that oxygen radicals produced by hypoxanthine and xanthine oxidase reaction produce an anticancer effect and that the VX2 carcinoma used in this study was more sensitive to oxygen radicals than normal muscle tissue.
Yoshikawa
T
T
First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
Kokura
S
S
Tainaka
K
K
Naito
Y
Y
Kondo
M
M
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002374:Catalase / Q000627:therapeutic use; D002417:Cattle; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D009132:Muscles / Q000378:metabolism / Q000473:pathology; D010212:Papilloma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000627:therapeutic use; D013481:Superoxides / Q000378:metabolism*; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014969:Xanthine Oxidase / Q000378:metabolism / Q000627:therapeutic use*
D016166:Free Radical Scavengers; D007042:Hypoxanthines; D011994:Recombinant Proteins; D017392:Thiobarbituric Acid Reactive Substances; D013481:Superoxides; D019271:Hypoxanthine; D002374:Catalase; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase